Aberrant splicing and transcriptional activity of TPP1 result in CLN2-like disorder.

[1]  Neil H. Parker,et al.  Diagnostic utility of transcriptome sequencing for rare Mendelian diseases , 2019, Genetics in Medicine.

[2]  S. Mole,et al.  Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease , 2019, Human mutation.

[3]  R. Santer,et al.  Validity of a rapid and simple fluorometric tripeptidyl peptidase 1 (TPP1) assay using dried blood specimens to diagnose CLN2 disease. , 2019, Clinica chimica acta; international journal of clinical chemistry.

[4]  B. Kosofsky,et al.  Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. , 2018, The Lancet. Child & adolescent health.

[5]  D. Ballon,et al.  Study of Intraventricular Cerliponase Alfa for CLN2 Disease , 2018, The New England journal of medicine.

[6]  Francesco Muntoni,et al.  Improving genetic diagnosis in Mendelian disease with transcriptome sequencing , 2016, Science Translational Medicine.

[7]  J. Friedman,et al.  TPP1 deficiency: Rare cause of isolated childhood-onset progressive ataxia , 2015, Neurology.

[8]  J. T. Dunnen,et al.  Autosomal Recessive Spinocerebellar Ataxia 7 (SCAR7) is Caused by Variants in TPP1, The Gene Involved in Classic Late‐Infantile Neuronal Ceroid Lipofuscinosis 2 Disease (CLN2 Disease) , 2013, Human mutation.

[9]  K. Sims,et al.  Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America. , 2013, Gene.

[10]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..